he Cancer Biopsy Market size was valued at USD 28.12 billion in 2023 and is projected to reach USD 85.03 billion by 2032, growing at a CAGR of 13.0% from 2024 to 2032, according to a recent report by SNS Insider. The rising global prevalence of cancer, advancements in precision oncology, and the growing adoption of non-invasive diagnostic techniques are key drivers shaping market growth.
The Cancer Biopsy Market is witnessing a major transformation, driven by an increasing focus on early diagnosis and personalized treatment approaches. With a strong emphasis on developing reliable and cost-effective biopsy tools, key players are introducing next-generation instruments and liquid biopsy platforms that enable rapid and accurate tumor profiling.
Moreover, the growing acceptance of liquid biopsy as a minimally invasive diagnostic solution has unlocked significant opportunities for detecting circulating tumor DNA (ctDNA) and RNA biomarkers. These innovative tools are helping clinicians track cancer progression, monitor therapeutic efficacy, and reduce the need for invasive tissue extraction procedures.
Get free Sample Report@ https://www.snsinsider.com/sample-request/1759
Kits and Consumables Lead the Product Segment
In 2023, kits and consumables dominated the market with a 61.8% share, supported by their essential role in accurate cancer diagnosis. The demand for ready-to-use biopsy kits, advanced sample preservation reagents, and tissue collection containers continues to rise across hospitals and research labs. These kits provide standardized solutions for efficient molecular testing and support diagnostic accuracy across various cancer types.
The instruments segment is anticipated to witness the highest CAGR of 9.3% during the forecast period. Continuous innovation in imaging systems, precision-guided biopsy needles, and automated tissue processors is enabling higher throughput and enhanced diagnostic yield. The integration of robotics and AI-guided tools is also improving accuracy, thereby reducing human error during biopsy procedures.
Tissue Biopsy Dominates While Liquid Biopsy Gains Traction
By type, tissue biopsy held the largest share of 61.7% in 2023. The segment’s growth is attributed to its proven effectiveness in histopathological analysis and the increasing demand for personalized medicine. Advanced tissue biopsy techniques allow oncologists to study genetic mutations and molecular changes for precision treatment planning.
Conversely, liquid biopsy is expected to record the fastest CAGR of 9.0% from 2024 to 2032. Its popularity stems from being a non-invasive alternative that enables real-time monitoring of cancer progression. The FDA’s approval of Guardant Health’s Guardant360 CDx liquid biopsy assay exemplifies regulatory support for cutting-edge diagnostics. Liquid biopsy is increasingly integrated into clinical workflows, supported by next-generation sequencing (NGS) and multi-omic testing technologies that facilitate faster and more accurate detection of tumor biomarkers.
Application Insights: Breast and Kidney Cancer Lead Growth
The breast cancer segment captured 15.7% of the market share in 2023, supported by rising awareness and advanced screening programs. Ongoing research into urinary exosomal biomarkers like MMP-1 and miR-21 highlights promising developments in early detection tools. Diagnostic innovation and the availability of new NGS-based assays are expected to accelerate adoption rates.
Meanwhile, the kidney cancer segment is projected to post the highest CAGR of 10.3% during the forecast period. Research initiatives by academic institutions, such as the University of Michigan Rogel Cancer Center and Ghent University, are advancing biomarker discovery and RNA sequencing for improved diagnostic accuracy. As precision oncology becomes mainstream, multi-analyte biomarker panels will redefine the standard of care for renal cancer detection.
Regional Outlook: North America Leads, Asia-Pacific to Grow Fastest
North America led the global market in 2023 with a 40.3% share, driven by strong healthcare infrastructure, early adoption of novel diagnostics, and favorable reimbursement frameworks. The region’s commitment to advancing early cancer detection is highlighted by funding activities such as Freenome’s USD 254 million capital raise to accelerate its single-cancer and multicancer early detection programs.
Europe follows closely, supported by regulatory approvals, government partnerships, and robust investments in healthcare R&D. In the UK and France, strategic collaborations between public institutions and private players are improving access to advanced biopsy technologies.
The Asia-Pacific region is expected to register the highest growth rate through 2032, fueled by rising cancer incidence, improving healthcare infrastructure, and entry of new diagnostic manufacturers. Rapid urbanization, expanding screening programs, and increasing awareness about early diagnosis are supporting regional market expansion.
Market Drivers
Rising incidence of cancer worldwide, particularly breast, lung, and colorectal types
Increasing use of precision medicine and targeted therapy approaches
Technological advancements in next-generation sequencing and digital pathology
Growing demand for minimally invasive diagnostic techniques
Favorable government initiatives and funding for cancer research
Recent Industry Developments
January 2024: Guardant Health announced new clinical data supporting its liquid biopsy platform’s use in early-stage cancer detection.
March 2024: Qiagen expanded its sample preparation and NGS product line to support faster biopsy analysis.
May 2024: Thermo Fisher Scientific introduced an automated biopsy tissue processor for high-throughput oncology testing.
Future Outlook
The Cancer Biopsy Market is poised for substantial expansion as healthcare providers embrace integrated diagnostics that combine molecular profiling and AI-driven analytics. Emerging trends such as the use of multi-omic liquid biopsy, automated image-guided systems, and biomarker-based screening are expected to redefine cancer diagnostics. With increasing clinical validation and regulatory approvals, biopsy technologies will play a vital role in improving survival rates and reducing cancer mortality worldwide.
FAQs on the Cancer Biopsy Market
Q1. What is driving the growth of the Cancer Biopsy Market?
The market is primarily driven by the rising global cancer burden, advancements in biopsy technologies such as liquid and NGS-based tests, and increasing adoption of personalized medicine for targeted therapy selection.
Q2. Which biopsy type is expected to grow the fastest?
Liquid biopsy is projected to grow at the highest rate due to its non-invasive nature, ability to provide real-time disease monitoring, and integration with next-generation sequencing.
Q3. Which region currently dominates the market?
North America leads the global market owing to its advanced healthcare systems, higher adoption of diagnostic technologies, and favorable reimbursement policies.
Q4. Who are some of the major players in the Cancer Biopsy Market?
Key players include Guardant Health, Qiagen, Thermo Fisher Scientific, Roche Diagnostics, Illumina, and Bio-Rad Laboratories.
Q5. What are the future trends in this market?
Future trends include AI-powered biopsy imaging, integration of liquid biopsy in precision oncology, and expansion of multi-cancer early detection tests through NGS technology
Other Trending Reports
Healthcare Waste Management Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
